|
시장보고서
상품코드
1890954
리팍시민(Rifaximin) 시장 : 적응증별, 제형별, 함유량별, 환자 그룹별, 최종사용자별, 제조 제조업체별, 유통 채널별, 지역별Rifaximin Market, By Indication, By Dosage Form, By Strength, By Patient Group, By End User, By Manufacturer Category, By Distribution Channel , By Geography |
||||||
리팍시민 시장은 2025년에 19억 4,000만 달러로 추정되며, 2032년까지 39억 8,000만 달러에 달할 것으로 예측됩니다. 2025년부터 2032년까지 CAGR 10.8%로 성장할 것으로 전망됩니다.
| 보고서 내용 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2024년 | 2025년 시장 규모: | 19억 4,000만 달러 |
| 과거 데이터 대상 기간: | 2020-2024년 | 예측 기간: | 2025-2032년 |
| 예측 기간 2025년부터 2032년까지 CAGR: | 10.80% | 2032년 예측치: | 39억 8,000만 달러 |
리팍시민 시장은 제약 산업에서 중요한 부분을 차지하고 있습니다. 리파마이신 SV를 기원으로 하는 반합성 항생제로 전신 흡수를 최소화하고 소화관에 작용하는 특성으로 독자적인 치료 효과를 발휘합니다. 리팍시민은 광범위 항균제로 작용하고 소화관 내에서 거의 흡수되지 않아 여행자 설사, 간성뇌증, 설사형 과민성 대장증후군(IBS-D) 등 다양한 장 질환의 치료에 특히 효과적입니다.
본 화합물의 작용기전은 세균의 RNA 중합효소에 결합하여 세균의 RNA 합성을 억제하여 장내 세균총 내 병원성 미생물을 효과적으로 제거하면서 유익균을 보호하는 점에 있습니다. 이러한 특징적인 약리학적 특성으로 인해 리팍시민은 전 세계 의료 전문가들이 선호하는 치료 옵션으로 자리매김하고 있으며, 선진국과 신흥국 시장에서 괄목할 만한 성장세를 보이고 있습니다. 정제, 경구 현탁액 등 다양한 제형이 시장에 존재하며, 지속적인 임상 연구와 규제 당국의 승인을 통해 여러 치료 영역에 걸쳐 적용 범위가 계속 확대되고 있습니다.
시장 역학
세계 리팍시민 시장의 성장 궤도를 뒷받침하는 주요 촉진요인은 주로 다음과 같습니다. 전 세계 소화기 질환 유병률 증가, 장 건강에 대한 인식 증가, 전신 노출과 내성 발현을 최소화하는 표적 항생제 요법의 채택 확대. 과민성대장증후군, 염증성 장질환, 간성 뇌병증과 같은 질환의 발병률 증가와 더불어, 이러한 질환에 취약한 고령화 인구의 증가는 리팍시민과 같은 효과적인 치료 옵션에 대한 큰 수요를 창출하고 있습니다. 또한, 국제 여행의 증가와 그에 따른 여행자 설사병의 위험은 시장 수요를 더욱 확대시키고 있습니다. 한편, 의료진은 리팍시민의 우수한 안전성 프로파일과 최소한의 약물 상호 작용을 이유로 리팍시민을 점점 더 선호하고 있습니다.
그러나 시장에는 심각한 제약도 존재합니다. 기존 항생제 대비 리팍시민의 높은 비용은 가격에 민감한 시장과 개발도상국에서의 접근성을 제한하고 있습니다. 특허 만료와 그에 따른 제네릭 의약품과의 경쟁은 시장 수익 성장에 지속적인 도전이 되고 있으며, 항생제 승인에 대한 엄격한 규제 요건은 신규 진입과 제품 변형에 대한 장벽으로 작용하고 있습니다. 또한, 특정 지역에서의 의료진의 인식 부족과 리팍시민의 국소 작용에도 불구하고 항생제 내성에 대한 우려로 인해 시장 침투가 계속 지연되고 있습니다. 그러나 비알코올성 지방간염(NASH), 크론병 유지요법, 재발성 게실염 예방 등 신흥 치료 영역의 적응증 확대를 통해 시장 상황은 여전히 큰 기회가 존재합니다. 새로운 제형 개발, 병용요법, 맞춤형 치료 접근법은 큰 성장 잠재력을 가지고 있으며, 신흥 시장의 의료비 증가와 정밀의료에 대한 관심 증가는 리팍시민 기반 치료제의 시장 확대와 혁신에 유리한 조건을 조성하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR)을 나타내는 세계 리팍시민(Refaximin) 시장에 대한 상세한 분석 정보를 제공합니다.
- 또한, 각 부문의 잠재적 수익기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 리팍시민 시장의 주요 업체를 프로파일링합니다.
- 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 도와줄 것입니다.
- 이 세계 리팍시민 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 리팍시민 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 범위
- 보고서 개요
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porters 분석
- 인수합병 동향
- 업계 동향
제4장 세계의 리팍시민 시장 : 적응증별, 2020-2032년
- 간성뇌증(HE)
- 설사형 과민성대장증후군(IBS-D)
- 여행자 설사
- 소장 세균 과잉 증식(SIBO)
- 염증성 장질환에 따른 설사(IBD-D)
- 클로스트리디오이데스 디피실리 관련 설사(보조적 사용)
- 기타 소화기 감염증
제5장 세계의 리팍시민 시장 : 제형별, 2020-2032년
- 정제
- 경구 현탁액
제6장 세계의 리팍시민 시장 : 함유량별, 2020-2032년
- 200 mg
- 400 mg
- 550 mg
제7장 세계의 리팍시민 시장 : 환자 그룹별, 2020-2032년
- 성인
- 노인
- 소아
제8장 세계의 리팍시민 시장 : 최종사용자별, 2020-2032년
- 병원
- 소화기내과 클리닉
- 외래 수술 센터
- 학술·연구기관
- 재택 헬스케어 서비스 제공자
제9장 세계의 리팍시민 시장 : 제조 제조업체별, 2020-2032년
- 브랜드 제품
- 제네릭
제10장 세계의 리팍시민 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 리팍시민 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Salix Pharmaceuticals
- Bausch Health Companies Inc
- Alfasigma SpA
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Cipla Limited
- Teva Pharmaceutical Industries Ltd
- Cosmo Pharmaceuticals NV
- Zambon Company SpA
- Granules India Limited
- Alembic Pharmaceuticals Limited
- Macleods Pharmaceuticals Limited
- MSN Laboratories Pvt Ltd
- Hetero Drugs
제13장 애널리스트의 추천사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고문헌 및 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Rifaximin Market is estimated to be valued at USD 1.94 Bn in 2025 and is expected to reach USD 3.98 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.94 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 10.80% | 2032 Value Projection: | USD 3.98 Bn |
The global rifaximin market represents a critical segment within the pharmaceutical industry, centered around a semi-synthetic antibiotic derived from rifamycin SV that exhibits unique therapeutic properties due to its minimal systemic absorption and targeted gastrointestinal action. Rifaximin operates as a broad-spectrum antimicrobial agent that remains largely unabsorbed in the gastrointestinal tract, making it particularly effective for treating various intestinal conditions including traveler's diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D).
The compound's mechanism involves binding to bacterial RNA polymerase, thereby inhibiting bacterial RNA synthesis and effectively eliminating pathogenic microorganisms within the gut microbiome while preserving beneficial bacteria. This distinctive pharmacological profile has positioned rifaximin as a preferred therapeutic option among healthcare professionals globally, driving substantial market growth across developed and emerging economies. The market encompasses various formulations including tablets and oral suspensions, with applications spanning multiple therapeutic areas that continue to expand through ongoing clinical research and regulatory approvals.
Market Dynamics
The global rifaximin market is propelled by several key drivers that collectively sustain its growth trajectory, primarily including the rising prevalence of gastrointestinal disorders worldwide, increasing awareness about gut health, and growing adoption of targeted antibiotic therapies that minimize systemic exposure and resistance development. The expanding incidence of conditions such as irritable bowel syndrome, inflammatory bowel disease, and hepatic encephalopathy, coupled with an aging global population more susceptible to these ailments, creates substantial demand for effective treatment options like rifaximin. Additionally, the growing trend of international travel and associated risks of traveler's diarrhea further amplifies market demand, while healthcare providers increasingly prefer rifaximin due to its favorable safety profile and minimal drug interactions.
However, the market faces significant restraints including the high cost of rifaximin compared to conventional antibiotics, which limits accessibility in price-sensitive markets and developing economies. Patent expirations and subsequent generic competition pose ongoing challenges to market revenue growth, while stringent regulatory requirements for antibiotic approvals create barriers for new entrants and product variations. Furthermore, limited awareness among healthcare professionals in certain regions and concerns about antibiotic resistance, despite rifaximin's localized action, continue to impede market penetration. Nevertheless, substantial opportunities exist within the market landscape, particularly through expanding applications in emerging therapeutic areas such as non-alcoholic steatohepatitis (NASH), Crohn's disease maintenance therapy, and prevention of recurrent diverticulitis. The development of novel formulations, combination therapies, and personalized treatment approaches presents significant growth potential, while increasing healthcare expenditure in emerging markets and growing emphasis on precision medicine create favorable conditions for market expansion and innovation in rifaximin-based therapeutics.
Key Features of the Study
- This report provides in-depth analysis of the global rifaximin market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global rifaximin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include leading Salix Pharmaceuticals, Bausch Health Companies Inc, Alfasigma SpA, Lupin Limited, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Cipla Limited, Teva Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, Zambon Company SpA, Granules India Limited, Alembic Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, MSN Laboratories Pvt Ltd, and Hetero Drugs
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global rifaximin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rifaximin market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Hepatic Encephalopathy (HE)
- Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Traveler's Diarrhea
- Small Intestinal Bacterial Overgrowth (SIBO)
- Inflammatory Bowel Disease-Associated Diarrhea (IBD-D)
- Clostridioides difficile-Associated Diarrhea (adjunct use)
- Other Gastrointestinal Infections
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Tablet
- Oral Suspension
- Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 200 mg
- 400 mg
- 550 mg
- Patient Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
- Pediatric
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Gastroenterology Clinics
- Ambulatory Surgical Centers
- Academic and Research Institutes
- Home Healthcare Providers
- Manufacturer Category Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Salix Pharmaceuticals
- Bausch Health Companies Inc
- Alfasigma SpA
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Cipla Limited
- Teva Pharmaceutical Industries Ltd
- Cosmo Pharmaceuticals NV
- Zambon Company SpA
- Granules India Limited
- Alembic Pharmaceuticals Limited
- Macleods Pharmaceuticals Limited
- MSN Laboratories Pvt Ltd
- Hetero Drugs
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Rifaximin Market, By Indication
- Global Rifaximin Market, By Dosage Form
- Global Rifaximin Market, By Strength
- Global Rifaximin Market, By Patient Group
- Global Rifaximin Market, By End User
- Global Rifaximin Market, By Manufacturer Category
- Global Rifaximin Market, By Distribution Channel
- Global Rifaximin Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Rifaximin Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hepatic Encephalopathy (HE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Traveler's Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Small Intestinal Bacterial Overgrowth (SIBO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inflammatory Bowel Disease-Associated Diarrhea (IBD-D)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Clostridioides difficile-Associated Diarrhea (adjunct use)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Rifaximin Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Rifaximin Market, By Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 200 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 400 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 550 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Rifaximin Market, By Patient Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Rifaximin Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastroenterology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Healthcare Providers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Rifaximin Market, By Manufacturer Category, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Rifaximin Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Rifaximin Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Salix Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alfasigma SpA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cosmo Pharmaceuticals NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zambon Company SpA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Granules India Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MSN Laboratories Pvt Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hetero Drugs
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
